Patents by Inventor Basma M. Ibrahim

Basma M. Ibrahim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LEVOTHYROXINE LIQUID FORMULATIONS
    Publication number: 20220096414
    Abstract: The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin, water, and an amine, and has a pH above the buffering range of the amine. The liquid formulation of the invention is stable and ready-to-use.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Applicant: Fresenius Kabi USA, LLC
    Inventors: Arunya USAYAPANT, Basma M. IBRAHIM
  • Levothyroxine liquid formulations
    Patent number: 11135190
    Abstract: The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: October 5, 2021
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • LEVOTHYROXINE LIQUID FORMULATIONS
    Publication number: 20210251931
    Abstract: The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Applicant: Fresenius Kabi USA, LLC
    Inventors: Arunya USAYAPANT, Basma M. IBRAHIM
  • LEVOTHYROXINE LIQUID FORMULATIONS
    Publication number: 20190336463
    Abstract: The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Applicant: Fresenius Kabi USA, LLC
    Inventors: Arunya USAYAPANT, Basma M. IBRAHIM
  • Levothyroxine liquid formulations
    Patent number: 10398669
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 3, 2019
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • LEVOTHYROXINE LIQUID FORMULATIONS
    Publication number: 20180153838
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Application
    Filed: September 11, 2017
    Publication date: June 7, 2018
    Applicant: Fresenius Kabi USA, LLC
    Inventors: Arunya USAYAPANT, Basma M. IBRAHIM
  • Levothyroxine liquid formulations
    Patent number: 9782376
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: October 10, 2017
    Assignee: Fresenius Kabi USA LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim